VNRXNYSEIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

VOLITIONRX LTD

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.17−0.01 (-3.50%)

Close on Oct 19, 2026

Market cap: $1.59M
P/E (TTM): –
Dividend yield: –

VOLITIONRX LTD income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Revenue	1.73	1.23	0.78	0.31	0.09	0.01	0.02	–	–	–	–	0.01	–	0.05	0
Research & Development	10	14	20	15	13	15	10	11	8.03	7.90	6.10	4.04	2.50	2.77	1.52
Selling, General & Admin	13	14	17	17	15	6.73	5.70	6.99	6.67	4.53	–	–	–	–	–
Selling & Marketing	3.92	5.36	6.84	6.58	3.72	1.07	0.97	1.17	0.84	0.35	–	–	–	–	–
General & Administrative	9.46	8.49	10	10	12	5.65	4.73	5.82	5.83	4.18	0.67	0.30	0.43	0.45	0.25
Operating Expenses	23	28	37	32	28	21	16	18	15	12	10	5.95	4.58	4.14	2.61
Operating Income	-22	-27	-36	-32	-28	-21	-16	-18	-15	-12	-10	-5.95	-4.58	-4.08	-2.61
Interest Expense	–	–	–	–	0.16	0.13	0.13	-0.11	0.07	0.02	–	–	–	–	–
Interest & Investment Income	0.00	0.01	0.09	0.13	0.00	0.05	0.11	–	–	–	–	–	–	–	–
Other Non-Operating Income	-1.76	-0.23	0.31	1.18	1.34	0.85	-0.06	-0.11	–	–	-0.02	0.01	–	–	–
Asset Impairment Charges	–	0	0	0	0	0	0	–	–	–	–	–	0.35	–	–
Gain (Loss) on Sale of Assets	0.00	-0.03	-0.02	0	–	-0.29	0	0.00	0.04	0.00	–	–	–	–	–
Income Tax Expense	–	–	–	–	–	–	–	–	–	–	0.00	–	–	–	–
Income from Continuing Operations	–	–	–	–	-27	-20	-16	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-24	-27	-36	–	-27	-20	-16	-18	–	–	–	–	–	-4.08	-2.61
Minority Interest in Earnings	–	-0.29	-0.36	0.33	–	–	–	–	–	–	–	–	–	–	–
Net Income	-23	-27	-36	-31	-27	-20	-16	-18	-15	-12	-9.53	-8.21	-3.71	-4.08	-2.61
Net Income to Common	–	-27	-35	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	–	–	–	–	-10.20	-9.00	-8.20	-11.40	-11.20	-10.40	-10.80	-12.20	-6.80	-8.80	-9.00
EPS (Diluted)(per share)	–	-6.20	-10.00	–	-10.20	-9.00	-8.20	-11.40	-11.20	-10.40	-10.80	-12.20	-6.80	-8.80	-9.00
Shares Outstanding (Basic, Weighted)(shares)	–	–	–	–	2.63	2.26	1.96	1.57	1.32	1.15	0.89	0.67	0.54	0.47	–
Shares Outstanding (Diluted, Weighted)(shares)	5.34	4.33	3.56	–	2.63	2.26	1.96	1.57	1.32	1.15	0.89	0.67	0.54	0.47	–
EBITDA	-21	-26	-35	-31	-27	-21	-15	-17	-14	-12	-9.77	-5.81	-4.43	-3.95	-2.49

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -790.2%
Net margin: -1043.1%
Return on equity, FY2025: 79.0%

Financial strength

Current ratio: 0.30
Debt to equity: -0.22
Debt to assets: 85.0%
Cash to current liabilities: 20.8%

Valuation

P/E ratio: –
Price to sales: 0.65
Price to book: –
Dividend yield: –